Norristown, PA (PRWEB) February 13, 2006 -- RheoGene, Inc., a preclinical stage biotechnology company using its RheoSwitch® Therapeutic System and DirectIt™ Recombinase platform technologies to develop novel cell- and gene-based therapeutics for cancer and CNS disorders, today announced that RheoGene President and CEO Thomas Tillett will participate as a panelist in the Focus Session “CNS Disorders: Alzheimer’s and Parkinson’s -- What is on the Horizon?” at the Eighth Annual BIO CEO & Investor Conference at the Waldorf Astoria Hotel in New York City on Wednesday, February 15, 2006 at 8:30 pm EST in the in the East Foyer.
